HIV prevention and transmission

Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound

9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.

Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study

9 October 2024. Related: Conference reports, HIV prevention and transmission.

HIVR4P 2024: Context of PrEP in Latin America

7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.

HIVR4P 2024: Introduction

7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.

Major update of UK PrEP guidelines online for public consultation

1 October 2024. Related: Special reports, Guidelines, HIV prevention and transmission.

NICE defers decision on CAB-LA as PrEP needing more information

27 September 2024. Related: Treatment access, HIV prevention and transmission.

Second lenacapavir PrEP study protected 99.9% of people in the PURPOSE 2 trial: ACT UP London challenge pricing

26 September 2024. Related: HIV prevention and transmission.

AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more

29 July 2024. Related: Conference reports, HIV prevention and transmission.

Low efficacy and high price of dapivirine ring: not included as PrEP in South African guidelines

27 July 2024. Related: Guidelines, HIV prevention and transmission.

Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV

26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.

Updated WHO guidelines for HIV PEP (July 2024)

23 July 2024. Related: Guidelines, HIV prevention and transmission.

New community call to challenge social settings that drive HIV-related stigma

20 July 2024. Related: Conference reports, HIV prevention and transmission, Treatment advocacy.

Lenacapavir PrEP: 100% efficacy in cisgender women sets new challenges for global pricing and access

24 June 2024. Related: HIV prevention and transmission.

New CDC guidelines recommend selected use of doxy-PEP in the US (2024)

4 June 2024. Related: Guidelines, HIV prevention and transmission.

Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all

12 February 2024. Related: Special reports, HIV prevention and transmission.

PrEP douche achieves more protective drug levels than 2:1:1 oral dosing

9 January 2024. Related: HIV prevention and transmission.

Latest figures published on HIV in the UK: 2023 report

1 December 2023. Related: Special reports, HIV prevention and transmission.

Oral tenofovir/FTC increases clearance of bNAb VRC01: implications for future research

1 December 2023. Related: PK and drug interactions, HIV prevention and transmission.

IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses

1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure-related research, Vaccines and microbicides.

IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density

1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.

EU approves cabotegravir as injectable PrEP

1 October 2023. Related: HIV prevention and transmission.

Mutations associated with resistance to dapivirine vaginal ring: reported in 7/38 women seroconverting in the open-label HOPE study

1 October 2023. Related: HIV prevention and transmission.

IAS 2023: Rapporteur summary Track C – prevention

1 September 2023. Related: Conference reports, HIV prevention and transmission.

Breakthrough HIV infection on PrEP with injectable cabotegravir

6 August 2023. Related: HIV prevention and transmission.

WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load

1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required

1 August 2023. Related: Conference reports, HIV prevention and transmission.

Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19

1 August 2023. Related: Conference reports, mpox (monkeypox), HIV prevention and transmission, Cure-related research, COVID-19: HIV and COVID-19 coinfection, COVID-19.

CAB-LA receives positive opinion for EU approval as PrEP

1 August 2023. Related: Antiretrovirals, HIV prevention and transmission.

PrEP for women and PrEP: new translations (June 2023)

1 August 2023. Related: HIV prevention and transmission.

NHS England approves use of F/TAF as alternative PrEP

1 June 2023. Related: HIV prevention and transmission.

Generic versions of injectable PrEP could enable access to CAB-LA in low-income countries

6 April 2023. Related: Antiretrovirals, HIV prevention and transmission.

CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults

10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.

56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021

1 February 2023. Related: HIV prevention and transmission.

Latest statistics on HIV in the UK: data for 2021

1 December 2022. Related: Special reports, HIV prevention and transmission.

Cabotegravir-LA submitted to EMA for use as PrEP in Europe

1 December 2022. Related: HIV prevention and transmission.

HIV seroconversions on PrEP in Australian study are linked to low adherence

1 September 2022. Related: HIV prevention and transmission.

Fantastic voyage: tracking adherence sensors in PrEP meds

1 July 2022. Related: HIV prevention and transmission.

ViiV licenses long-acting cabotegravir (CAB-LA) for generic access

1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.

A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton

2 May 2022. Related: HIV prevention and transmission.

Zimbabwe decriminalises HIV transmission

2 May 2022. Related: HIV prevention and transmission, Other news.

CROI 2022: UK study shows PEP is started earlier using home starter packs

1 April 2022. Related: Conference reports, HIV prevention and transmission.

HIV vaccine study using mRNA technology starts in the US

1 April 2022. Related: HIV prevention and transmission.

South Africa approves dapivirine vaginal ring for HIV prevention

1 April 2022. Related: HIV prevention and transmission.

CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access

1 March 2022. Related: Conference reports, HIV prevention and transmission.

CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study

1 March 2022. Related: Conference reports, HIV prevention and transmission.

EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?

20 December 2021. Related: Conference reports, HIV prevention and transmission.

US FDA approves long-acting cabotegravir injections for PrEP: price set at $22,000 a year

20 December 2021. Related: HIV prevention and transmission.

56 Dean Street reports M184V common with recent low adherence to PrEP and seven transmissions with good adherence

20 December 2021. Related: HIV prevention and transmission.

EACS 2021: a call for collaborations and for both HIV and COVID-19

31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

Gilead withdraws application for F/TAF as PrEP in the EU

31 October 2021. Related: HIV prevention and transmission.

Imbokodo trial results highlight challenge of developing an HIV vaccine and urgent need for access to proven prevention tools

17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.

Moderna registers HIV vaccine study

17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.

IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies

1 August 2021. Related: Conference reports, HIV prevention and transmission, Research studies.

IAS 2021: New demands for better transgender heath care: No data no more

1 August 2021. Related: Conference reports, HIV prevention and transmission.

Phase 1 HIV mosaic vaccine study launched at Oxford university

1 August 2021. Related: HIV prevention and transmission, Vaccines and microbicides.

HIV bNAbs prevent intravenous exposure to SHIV in macaques as PrEP

1 June 2021. Related: HIV prevention and transmission.

CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission

12 March 2021. Related: Conference reports, HIV prevention and transmission.

R4P virtual conference (2021)

24 February 2021. Related: Conference reports, HIV prevention and transmission.

VRC01 antibody only prevents minority of HIV infections: AMP study results

24 February 2021. Related: Conference reports, HIV prevention and transmission.

Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)

24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.

Post navigation